RAIR–ATC Transcriptional Axis and Drug-Response Data for Thyroid Cancer

Supplementary data from a study investigating the molecular continuum between radioiodine-refractory and anaplastic thyroid cancer. The research integrated RNA-seq and microarray cohorts from TCGA-THCA and other sources to derive gene modules and predict drug sensitivity. The dataset, authored by Siying Wang and published on figshare under CC-BY-4.0, is 4.2 MB and was last updated in May 2026.

Use Cases

• Identifying drug-class vulnerabilities based on RAIR signature scores.
• Training multimodal ridge models for drug-response prediction using cell and drug features.
• Analyzing pathway activity associations with hypoxia and interferon/inflammatory programs.
• Prioritizing targeted therapies like VEGFR/KDR and RAF/BRAF inhibitors for translational evaluation.

Strengths

• Integrates data from multiple cohorts including TCGA-THCA and five ATC cohorts.
• Includes PRISM drug-response AUC data from 18 thyroid cell lines.
• Provides an interpretable multimodal ridge model framework for prediction.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is contained within a PDF file, which may require extraction and parsing.

Provenance

Source

figshare

Collection Method

Integrated RNA-seq and microarray cohorts from TCGA-THCA, RAIR vs. radioiodine-avid PTC cohort, and five ATC cohorts.

Freshness

Last updated 2026-05-18 05:30:50; freshness should be verified.